Time is of the essence when it comes to developing cancer therapeutics. Humanized mouse models are powerful tools for evaluating preclinical applications, including the safety and efficacy of immune checkpoint inhibitors and other compounds that act on human immune system components to fight cancer cells.
Enter the HuCD34-NCG mouse, the newest research model in the Charles River portfolio created to support your translational oncology research. Developed from our strain of triple-immunodeficient NCG mice, the HuCD34-NCG expresses a human-like immune system, making it an ideal in vivo platform to evaluate the effectiveness of compounds that modulate human immune cells. Each study-ready mouse is validated and tested for human immune cell engraftment, so it is ready for you to evaluate your immunotherapeutic compounds in tumor xenograft studies.
Optimal for long-term studies, humanized mice like the HuCD34-NCG can save you critical time and money on the road to clinic. Get started by checking out our portfolio and connecting with our oncology team. With more than 25 years of experience conducting tumor studies, our scientists are uniquely qualified to help you maximize your investment with tailored study designs, assays, and interpretation of results.